1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
2. Junttila MR, Evan GI. p53--a Jack of all trades but master of none. Nat Rev Cancer 2009;9:821-9
3. Brooks CL, Li M, Hu M, Shi Y, Gu W. The p53--Mdm2--HAUSP complex is involved in p53 stabilization by HAUSP. Oncogene 2007;26:7262-6
4. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66
5. Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol 2013;14:297-306
6. Dürst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions.
Proc Natl Acad Sci U S A 1983;80:3812-5
7. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 1984;3:1151-7
8. Gissmann L, Boshart M, Dürst M, Ikenberg H, Wagner D, zur Hausen H. Presence of human papillomavirus in genital tumors. J Invest Dermatol 1984;83:26s-8s
9. Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol 2009;19:97-113
10. Cai Q, Lv L, Shao Q, Li X, Dian A. Human papillomavirus early proteins and apoptosis.
Arch Gynecol Obstet 2013;287:541-8
11. Tommasino M. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol 2014;26:13-21
12. Steenbergen RD, de Wilde J, Wilting SM, Brink AA, Snijders PJ, Meijer CJ.
HPV-mediated transformation of the anogenital tract. J Clin Virol 2005;32 Suppl 1:S25-33 13. Nair S, Pillai MR. Human papillomavirus and disease mechanisms: relevance to oral and
14. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al.
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27
15. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73
16. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection:
unresolved issues. Nat Rev Cancer 2007;7:11-22
17. Grm HS, Massimi P, Gammoh N, Banks L. Crosstalk between the human papillomavirus E2 transcriptional activator and the E6 oncoprotein. Oncogene 2005;24:5149-64
18. Gammoh N, Grm HS, Massimi P, Banks L. Regulation of human papillomavirus type 16 E7 activity through direct protein interaction with the E2 transcriptional activator. J Virol 2006;80:1787-97
19. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004;364:1678-83 20. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, et al. Variations in
the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119:2677-84
21. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36
22. Talis AL, Huibregtse JM, Howley PM. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem 1998;273:6439-45
23. Pim D, Banks L. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS 2010;118:471-93
24. Patel D, Huang SM, Baglia LA, McCance DJ. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 1999;18:5061-72 25. Kumar A, Zhao Y, Meng G, Zeng M, Srinivasan S, Delmolino LM, et al. Human
papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3.
Mol Cell Biol 2002;22:5801-12
26. Jha S, Vande Pol S, Banerjee NS, Dutta AB, Chow LT, Dutta A. Destabilization of TIP60 by human papillomavirus E6 results in attenuation of TIP60-dependent transcriptional regulation and apoptotic pathway. Mol Cell 2010;38:700-11
27. Yuji Yaginuma MY, Aoi Tokuda. USP15 inhibits HPV16 E6 degradation and catalytically inactive USP15 has reduced inhibitive activity. Volume 62. Acta viologica2018. p in press.
28. Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7 29. Yaginuma Y, Yoda K, Ogawa K. Characterization of physical binding between human
papillomavirus 18 protein E7 and centromere protein C. Oncology 2010;79:219-28
30. Yaginuma Y, Eguchi A, Yoshimoto M, Ogawa K. The PxDLLCxE sequence in conserved region 2 of human papilloma virus 18 protein E7 is required for E7 binding to centromere protein C. Oncology 2012;83:210-7
31. Yaginuma Y, Yoshimoto M, Eguchi A, Tokuda A, Takahashi S. The human papillomavirus18 E7 protein inhibits CENP-C binding to α-satellite DNA. Virus Res 2015;205:27-32
32. Costa C, Espinet B, Molina MA, Salgado R, Salido M, Baró T, et al. Analysis of gene status in cervical dysplastic lesions and squamous cell carcinoma using tissue microarrays.
Histol Histopathol 2009;24:821-9
33. Tornesello ML, Annunziata C, Buonaguro L, Losito S, Greggi S, Buonaguro FM. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. J Transl Med 2014;12:255
34. Cheung TH, Lo KW, Yim SF, Chan LK, Heung MS, Chan CS, et al. Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol Oncol 2004;93:621-7
35. D'Andrilli G, Bovicelli A, Paggi MG, Giordano A. New insights in endometrial carcinogenesis. J Cell Physiol 2012;227:2842-6
36. Yaginuma Y, Yamashita T, Ishiya T, Morizaki A, Katoh Y, Takahashi T, et al. Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers. Mol Carcinog 2000;27:110-6
37. Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology
38. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-30
39. Simpkins SB, Peiffer-Schneider S, Mutch DG, Gersell D, Goodfellow PJ. PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. Gynecol Oncol 1998;71:391-5
40. Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, Akslen LA, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 2001;91:22-6
41. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998;58:3526-8
42. Moreno-Bueno G, Hardisson D, Sánchez C, Sarrió D, Cassia R, García-Rostán G, et al.
Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002;21:7981-90
43. Enomoto T, Inoue M, Perantoni AO, Buzard GS, Miki H, Tanizawa O, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 1991;51:5308-14
44. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, et al. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 1993;53:1906-10
45. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011;17:1331-40
46. Llobet D, Pallares J, Yeramian A, Santacana M, Eritja N, Velasco A, et al. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol 2009;62:777-85
47. Haruta S, Furukawa N, Yoshizawa Y, Tsunemi T, Nagai A, Kawaguchi R, et al. Molecular genetics and epidemiology of epithelial ovarian cancer (Review). Oncol Rep 2011;26:1347-56
48. Lauchlan SC. The secondary Müllerian system. Obstet Gynecol Surv 1972;27:133-46
49. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-43
50. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol 2011;42:918-31
51. Berns EM, Bowtell DD. The changing view of high-grade serous ovarian cancer. Cancer Res 2012;72:2701-4
52. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 2009;40:1213-23
53. Gurung A, Hung T, Morin J, Gilks CB. Molecular abnormalities in ovarian carcinoma:
clinical, morphological and therapeutic correlates. Histopathology 2013;62:59-70
54. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al.
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-6
55. Piek JM, van Diest PJ, Zweemer RP, Kenemans P, Verheijen RH. Tubal ligation and risk of ovarian cancer. Lancet 2001;358:844
56. Yamamoto Y, Ning G, Howitt BE, Mehra K, Wu L, Wang X, et al. In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells. J Pathol 2016;238:519-30
57. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al.
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007;31:161-9
58. Shaw PA, Rouzbahman M, Pizer ES, Pintilie M, Begley H. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol 2009;22:1133-8
59. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992;52:4196-9
60. Roh MH, Yassin Y, Miron A, Mehra KK, Mehrad M, Monte NM, et al. High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol 2010;23:1316-24
Cancer 2010;10:803-8
62. Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15
63. Vang R, Shih IM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma:
pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
Adv Anat Pathol 2009;16:267-82
64. Smolle E, Taucher V, Pichler M, Petru E, Lax S, Haybaeck J. Targeting signaling pathways in epithelial ovarian cancer. Int J Mol Sci 2013;14:9536-55
65. Nakamura K, Nakayama K, Ishibashi T, Ishikawa N, Ishikawa M, Katagiri H, et al.
KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions. Int J Mol Sci 2016;17
66. Mandai M, Matsumura N, Baba T, Yamaguchi K, Hamanishi J, Konishi I. Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Lett 2011;310:129-33
67. Kobayashi H, Sumimoto K, Moniwa N, Imai M, Takakura K, Kuromaki T, et al. Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 2007;17:37-43
68. Baranov VS, Ivaschenko TE, Liehr T, Yarmolinskaya MI. Systems genetics view of endometriosis: a common complex disorder. Eur J Obstet Gynecol Reprod Biol 2015;185:59-65
69. Yamaguchi K, Mandai M, Toyokuni S, Hamanishi J, Higuchi T, Takakura K, et al.
Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 2008;14:32-40
70. Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000;60:7052-6
71. Castiblanco G A, Pires N Y, Wistuba O I, Riquelme S E, Andrade M L, Corvalán R A.
[Pathogenic role of PTEN tumor suppressor gene in ovarian cancer associated to endometriosis]. Rev Med Chil 2006;134:271-8
72. Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC. PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol 2006;101:71-5
73. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-43
74. Samartzis EP, Noske A, Dedes KJ, Fink D, Imesch P. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci 2013;14:18824-49
75. Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, et al.
Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.
Clin Cancer Res 2011;17:1521-34
76. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al.
Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81 77. Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, et al. A limited panel of
immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009;33:14-21
78. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suárez A, Armas A. beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999;155:527-36
79. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol 2006;19:83-9
80. Kobayashi H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, et al. The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary.
Int J Gynecol Cancer 2009;19:471-9
81. Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 1997;79:1581-6 82. Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, et al. Molecular
HER2 targeting in 19% of carcinomas. J Pathol 2013;229:111-20
83. Smith JS, Tachibana I, Lee HK, Qian J, Pohl U, Mohrenweiser HW, et al. Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 2000;29:16-25
84. Kim YJ, Cho YE, Kim YW, Kim JY, Lee S, Park JH. Suppression of putative tumour suppressor gene GLTSCR2 expression in human glioblastomas. J Pathol 2008;216:218-24 85. Okahara F, Itoh K, Nakagawara A, Murakami M, Kanaho Y, Maehama T. Critical role of
PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3,4,5-trisphosphate signals and tumorigenic transformation. Mol Biol Cell 2006;17:4888-95
86. Rifatbegovic F, Frech C, Abbasi MR, Taschner-Mandl S, Weiss T, Schmidt WM, et al.
Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression. Int J Cancer 2017
87. Kim JY, Cho YE, Park JH, Lee S. Expression of GLTSCR2/Pict-1 in squamous cell carcinomas of the skin. Arch Dermatol Res 2013;305:797-804
88. Zhang L, Farrell JJ, Zhou H, Elashoff D, Akin D, Park NH, et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology 2010;138:949-57.e1-7
89. Cho YE, Lee HL, Lim SJ, Kim YW, Choe BK, Lee S, et al. Suppression of GLTSCR2 expression in renal cell carcinomas. Pathol Res Pract 2016;212:120-4
90. Kim JY, Cho YE, Kim GY, Lee HL, Lee S, Park JH. Down-regulation and aberrant cytoplasmic expression of GLTSCR2 in prostatic adenocarcinomas. Cancer Lett 2013;340:134-40
91. Moon A, Lim SJ, Jo YH, Lee S, Kim JY, Lee J, et al. Downregulation of GLTSCR2 expression is correlated with breast cancer progression. Pathol Res Pract 2013;209:700-4 92. Zhang J, Wang Q, Liu Y, Sun K, Zhang B, Jin Q, et al. The expression of GLTSCR2 in
cervical intra-epithelial lesion and cancer. Arch Gynecol Obstet 2015;291:413-8
93. Yoshimoto M, Tokuda A, Nishiwaki K, Sengoku K, Yaginuma Y. The protein interacting with carboxyl terminus-1 codon 389 polymorphism impairs protein interacting with carboxyl terminus-1 function and is a risk factor for uterine cervical cancer. Mol Carcinog
2017;56:1484-92
94. Merritt MA, Parsons PG, Newton TR, Martyn AC, Webb PM, Green AC, et al. Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer.
BMC Cancer 2009;9:378
95. Okahara F, Ikawa H, Kanaho Y, Maehama T. Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J Biol Chem 2004;279:45300-3
96. Yim JH, Kim YJ, Ko JH, Cho YE, Kim SM, Kim JY, et al. The putative tumor suppressor gene GLTSCR2 induces PTEN-modulated cell death. Cell Death Differ 2007;14:1872-9 97. Chen H, Mei L, Zhou L, Zhang X, Guo C, Li J, et al. Moesin-ezrin-radixin-like protein
(merlin) mediates protein interacting with the carboxyl terminus-1 (PICT-1)-induced growth inhibition of glioblastoma cells in the nucleus. Int J Biochem Cell Biol 2011;43:545-55
98. Kim JY, Cho YE, Park JH. The Nucleolar Protein GLTSCR2 Is an Upstream Negative Regulator of the Oncogenic Nucleophosmin-MYC Axis. Am J Pathol 2015;185:2061-8 99. Kim JY, Park JH, Lee S. GLTSCR2 contributes to the death resistance and invasiveness of
hypoxia-selected cancer cells. FEBS Lett 2012;586:3435-40
100. Kim JY, Seok KO, Kim YJ, Bae WK, Lee S, Park JH. Involvement of GLTSCR2 in the DNA Damage Response. Am J Pathol 2011;179:1257-64
101. Lee S, Kim JY, Kim YJ, Seok KO, Kim JH, Chang YJ, et al. Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal stresses. Cell Death Differ 2012;19:1613-22
102. Lee S, Cho YE, Kim SH, Kim YJ, Park JH. GLTSCR2 promotes the nucleoplasmic translocation and subsequent degradation of nucleolar ARF. Oncotarget 2017;8:16293-302 103. Chen H, Duo Y, Hu B, Wang Z, Zhang F, Tsai H, et al. PICT-1 triggers a pro-death
autophagy through inhibiting rRNA transcription and AKT/mTOR/p70S6K signaling pathway. Oncotarget 2016;7:78747-63
104. Sasaki M, Kawahara K, Nishio M, Mimori K, Kogo R, Hamada K, et al. Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. Nat Med 2011;17:944-51
105. Uchi R, Kogo R, Kawahara K, Sudo T, Yokobori T, Eguchi H, et al. PICT1 regulates TP53
106. Ishibashi M, Kogo R, Shibata K, Ueo H, Uchi R, Matsumura T, et al. Clinical significance of PICT1 in patients of hepatocellular carcinoma with wild-type TP53. Ann Surg Oncol 2013;20 Suppl 3:S537-44
107. Nishida M, Kasahara K, Kaneko M, Iwasaki H, Hayashi K. [Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors]. Nihon Sanka Fujinka Gakkai Zasshi 1985;37:1103-11
108. Zaman MM, Nomura T, Takagi T, Okamura T, Jin W, Shinagawa T, et al.
Ubiquitination-deubiquitination by the TRIM27-USP7 complex regulates tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol 2013;33:4971-84
109. Canning M, Boutell C, Parkinson J, Everett RD. A RING finger ubiquitin ligase is protected from autocatalyzed ubiquitination and degradation by binding to ubiquitin-specific protease USP7. J Biol Chem 2004;279:38160-8
110. Fernández-Montalván A, Bouwmeester T, Joberty G, Mader R, Mahnke M, Pierrat B, et al.
Biochemical characterization of USP7 reveals post-translational modification sites and structural requirements for substrate processing and subcellular localization. FEBS J 2007;274:4256-70
111. Pappas K, Xu J, Zairis S, Resnick-Silverman L, Abate F, Steinbach N, et al. p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes. Mol Cancer Res 2017;15:1051-62
112. Fischer M, Grossmann P, Padi M, DeCaprio JA. Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks. Nucleic Acids Res 2016;44:6070-86
113. Walerych D, Lisek K, Sommaggio R, Piazza S, Ciani Y, Dalla E, et al. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol 2016;18:897-909
114. Yonamine K, Hayashi K, Iida T. Establishment and characterization of human ovarian clear cell adenocarcinoma cell line (SMOV-2), and its cytotoxity by anticancer agents.
Hum Cell 1999;12:139-48
115. Brachmann RK, Vidal M, Boeke JD. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci U S A 1996;93:4091-5
116. Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, et al.
Type-specific cell line models for type-specific ovarian cancer research. PLoS One 2013;8:e72162
117. Skaug V, Ryberg D, Kure EH, Arab MO, Stangeland L, Myking AO, et al. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 2000;6:1031-7
118. Ahuja D, Sáenz-Robles MT, Pipas JM. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 2005;24:7729-45
119. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J, et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002;416:648-53
120. Cummins JM, Rago C, Kohli M, Kinzler KW, Lengauer C, Vogelstein B. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 2004;428:1 p following 486 121. Wang J, Huo K, Ma L, Tang L, Li D, Huang X, et al. Toward an understanding of the
protein interaction network of the human liver. Mol Syst Biol 2011;7:536
122. Sheng Y, Saridakis V, Sarkari F, Duan S, Wu T, Arrowsmith CH, et al. Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat Struct Mol Biol 2006;13:285-91 123. Sarkari F, Sanchez-Alcaraz T, Wang S, Holowaty MN, Sheng Y, Frappier L.
EBNA1-mediated recruitment of a histone H2B deubiquitylating complex to the Epstein-Barr virus latent origin of DNA replication. PLoS Pathog 2009;5:e1000624
124. Lim KH, Park JJ, Gu BH, Kim JO, Park SG, Baek KH. HAUSP-nucleolin interaction is regulated by p53-Mdm2 complex in response to DNA damage response. Sci Rep 2015;5:12793
125. Wang P, Meng W, Han SC, Li CC, Wang XJ. The nucleolar protein GLTSCR2 is required for efficient viral replication. Sci Rep 2016;6:36226
126. Pasche B, Knobloch TJ, Bian Y, Liu J, Phukan S, Rosman D, et al. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA 2005;294:1634-46
127. Ohbu M, Saegusa M, Okayasu I. Apoptosis and cellular proliferation in oesophageal squamous cell carcinomas: differences between keratinizing and nonkeratinizing types.
Virchows Arch 1995;427:271-6
Cell Carcinoma Is Associated with Poor Clinical Outcome. Tuberc Respir Dis (Seoul) 2017;80:179-86
129. Kalt I, Levy A, Borodianskiy-Shteinberg T, Sarid R. Nucleolar localization of GLTSCR2/PICT-1 is mediated by multiple unique nucleolar localization sequences. PLoS One 2012;7:e30825
130. Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 1998;18:7288-93
131. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 1991;67:547-56 132. Yaginuma Y, Westphal H. Analysis of the p53 gene in human uterine carcinoma cell lines.
Cancer Res 1991;51:6506-9
133. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9
134. Lechner MS, Laimins LA. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 1994;68:4262-73
135. Massimi P, Banks L. Repression of p53 transcriptional activity by the HPV E7 proteins.
Virology 1997;227:255-9
136. Ahmed NY, Isaac RH. P53 Expression in Endometrial Hyperplasia and Endometrial Carcinoma. Volume 14. Zanco J. Med. Sci.2010. p 28-34.
137. Corney DC, Flesken-Nikitin A, Choi J, Nikitin AY. Role of p53 and Rb in ovarian cancer.
Adv Exp Med Biol 2008;622:99-117
138. Hara MR, Kovacs JJ, Whalen EJ, Rajagopal S, Strachan RT, Grant W, et al. A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1.
Nature 2011;477:349-53
139. McCloskey R, Menges C, Friedman A, Patel D, McCance DJ. Human papillomavirus type 16 E6/E7 upregulation of nucleophosmin is important for proliferation and inhibition of differentiation. J Virol 2010;84:5131-9
140. Shi SL, Liang Y, Li QF, Liu QR, Jing GJ, Wang SY, et al. Localization of nucleophosmin in nuclear matrix and changes in its expression during the differentiation of human neuroblastoma induced by retinoic acid. J Cell Biochem 2010;111:67-74